JP Morgan Chase
MPLT

JP Morgan Chase’s MapLight Therapeutics MPLT Stock Holding History

JP Morgan Chase’s Portfolio MPLT Stock Details MPLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$149K Sell
4,332
-3,537
-45% -$102K ﹤0.01% 5775
2026
Q1 		$147K Buy
7,869
+1,126
+17% +$20.1K ﹤0.01% 5634
2025
Q4 		$118K Buy
+6,743
New +$113K ﹤0.01% 5794

Other funds holding MPLT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $131M AUM 86.64% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase's MPLT Position: Q2 2026 in Review

JP Morgan Chase reduced its MapLight Therapeutics (MPLT) stake by 45% in Q2 2026, selling an estimated $102K and leaving 4,332 shares worth $149K. The position accounts for ﹤0.01% of the portfolio, ranked #5775.

JP Morgan Chase first reported a position in MPLT in Q4 2025 and has held it in 3 quarters since. 105 funds tracked by Wall St. Rank hold MPLT as of Q2 2026.

  • JP Morgan Chase held 4,332 shares of MapLight Therapeutics worth $149K as of Q2 2026.
  • JP Morgan Chase sold 3,537 MapLight Therapeutics shares in Q2 2026, an estimated $102K.
  • MapLight Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #5775 holding.
  • JP Morgan Chase first reported a position in MapLight Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 105 funds tracked by Wall St. Rank held MapLight Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.